The fourth-quarter earnings season for the biotech sector is in full swing this week. A few bigwigs have already reported results. Among these, Bristol Myers reported better-than-expected fourth-quarter results but provided a lackluster guidance for 2025. Regeneron also beat on fourth-quarter earnings and sales and initiated a quarterly dividend. Amgen’s fourth-quarter results were decent as it beat on earnings as well as sales. However, investors were disappointed by a regulatory setback for its obesity dr ...